IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

Fam-Trastuzumab Deruxtecan-NXKI

fam-trastuzumab deruxtecan-nxki for injection
for intravenous use Initial U.S. Approval: 2019

fam-trastuzumab deruxtecan-nxki for Injection is a “used to treat Metastatic Breast Cancer and Locally Advanced or Metastatic Gastric Cancer“. ENHERTU for injection is a “prescription medicine. It is available in “form and strength” For injection: 100 mg lyophilized powder in a single-dose vial. ENHERTU for injection can be obtained in India upon request.

To inquire about the “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”

Facts about your medicine

Active fam-trastuzumab deruxtecan-nxki
Approval Date:
Proprietary Name: On Request
Active Ingredient(s): fam-trastuzumab deruxtecan-nxki
Dosage Forms And Strengths: For injection: 100 mg lyophilized powder in a single-dose via
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For Fam-Trastuzumab Deruxtecan-NXKI

Know about product usage and updates

Enhertu (fam-trastuzumab deruxtecan-nxki) intravenous infusion was originally approved in 2019. In 2022, CDER approved Enhertu to treat patients with unresectable or metastatic HER2-low breast cancer through the Accelerated Approval program. This is the first approved therapy targeted to patients with the HER2-low breast cancer subtype, a newly defined subset of HER2-negative breast cancer in which there are some HER2 proteins on the cell surface, but not enough to be classified as HER2-positive.

Enhertu was also approved in 2022 for adults with unresectable or metastatic HER2-positive breast cancer who had received a prior anti-HER2-based regimen; as well as for adults with unresectable or metastatic non-small cell lung cancer whose tumors have an activating HER2 mutation who received prior systemic (treating the whole body) therapy.

Who is the supplier of Specialty drug in India?

Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

ENHERTU (fam-trastuzumab deruxtecan-nxki) for injection, for intravenous use Initial U.S. Approval: 2019

Related posts for product review usage

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398